UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 189

Sortiert nach

P672 Switching out of class or to another anti-TNF agent is the most effective strategy in IBD patients with immunogenicity against anti-TNF antibodies

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i803-i804

2023

Volltextzugriff (PDF)

P702 Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i834-i835

2023

Volltextzugriff (PDF)

relatos de la pasión como memoria y narración ritual

Revista de filosofía de la Universidad de Costa Rica, 2023-05, Vol.62 (163), p.277-290

Zúñiga Valerio, Hanzel J.

2023

Volltextzugriff (PDF)

P793 Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysis

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i925-i926

2023

Volltextzugriff (PDF)

“Después de Jesús”: la fe en la resurrección y la naciente cristología

Revista de filosofía de la Universidad de Costa Rica, 2021-11, Vol.60 (158), p.123-134

Zúñiga Valerio, Hanzel J.

2021

Volltextzugriff (PDF)

DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i92-i93

2024

Volltextzugriff (PDF)

Fatigue in sarcoidosis and exercise tolerance, dyspnea, and quality of life

Advances in experimental medicine and biology, 2015-01, Vol.833, p.31

2015

Volltextzugriff (PDF)

N17 Frequency of infliximab-induced skin lesions and their impact on quality of life in inflammatory bowel disease patients treated with infliximab

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S564-S565

2019

Volltextzugriff (PDF)

Pre-Courtship Behavior and the Effect of Age on Its Duration in Diatraea magnifactella (Lepidoptera: Crambidae)

The Florida entomologist, 2016-09, Vol.99 (3), p.352-354

2016

Volltextzugriff (PDF)

P603 Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease

Journal of Crohn's and colitis, 2018-01, Vol.12 (supplement_1), p.S414-S414

2018

Volltextzugriff (PDF)

P177 Lower vedolizumab trough levels before interval shortening are not predictive of success of the intervention

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S226-S227

2020

Volltextzugriff (PDF)

P344 Effectiveness and safety of switching patients with inflammatory bowel disease from originator infliximab to CT-P13: systematic review and meta-analysis

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S367-S368

2021

Volltextzugriff (PDF)

P720 Drug survival of first-line biologics in inflammatory bowel disease: large single-centre experience from UR-CARE

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i850-i851

2023

Volltextzugriff (PDF)

Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn’s and Colitis Organisation [ECCO] Position Paper

Journal of Crohn's and colitis, 2023-04, Vol.17 (3), p.311-317

2023

Volltextzugriff (PDF)

Sorry Works! Disclosure, Apology, and Relationships Prevent Medical Malpractice Claims

Mayo Clinic Proceedings, 2009-05, Vol.84 (5), p.484-484

Hanzel, Matthew J.

2009

Volltextzugriff (PDF)

Baseline Data and Measurement Instruments Reported In Observational Studies In Inflammatory Bowel Disease: Results From A Systematic Review

Journal of Crohn's and colitis, 2024-06, Vol.18 (6), p.875

2024

Volltextzugriff (PDF)

P041 Characterization of cytokine and drug concentrations in serum, mucosa and faeces during induction treatment of moderate-to-severe ulcerative colitis with anti-TNF monoclonal antibodies

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i157-i158

2022

Volltextzugriff (PDF)

A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence

Journal of Crohn's and colitis, 2022-11, Vol.16 (10), p.1511-1522

2022

Volltextzugriff (PDF)

Sorry Works! Disclosure, Apology, and Relationships Prevent Medical Malpractice Claims

Mayo Clinic proceedings, 2009-05, Vol.84 (5), p.484-484

Hanzel, Matthew J., JD

2009

Volltextzugriff (PDF)

P311 Reliability of computed tomography enterography for evaluation of stricturing Crohn’s disease: Development of a Crohn’s disease stricture index

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i453-i453

2023

Volltextzugriff (PDF)

P495 Vedolizumab trough concentrations and histological remission in Ulcerative Colitis: Results from the LOVE-UC study

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i625-i626

2023

Volltextzugriff (PDF)

P686 Neither high infliximab maintenance doses nor high trough levels trigger skin side effects of the drug: a prospective cross-sectional study

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S463-S464

2019

Volltextzugriff (PDF)

DOP63 Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i108-i109

2022

Volltextzugriff (PDF)

Physician, Protect Thyself: 7 Simple Ways NOT to Get Sued for Medical Malpractice

Mayo Clinic proceedings, 2007, Vol.82 (7), p.895-895

Hanzel, Matthew J., JD

2007

Volltextzugriff (PDF)

Genetically determined thrombophilia as a cause of acute abdomen

Rozhledy v chirurgii, 2014-05, Vol.93 (5), p.271

2014

Volltextzugriff (PDF)

1 – 25 von 189

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(165)
Mit Volltextzugriff
(161)

Publikationsform

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

P672 Switching out of class or to another anti-TNF agent is the most effective strategy in IBD patients with immunogenicity against anti-TNF antibodies

P702 Clinical and biomarker remission is maintained after switch from monthly dosed intravenous to subcutaneous maintenance treatment with vedolizumab in Inflammatory Bowel Disease

relatos de la pasión como memoria y narración ritual

P793 Infliximab and prevention of colectomy in acute severe ulcerative colitis: an individual patient data meta-analysis

“Después de Jesús”: la fe en la resurrección y la naciente cristología

DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial

Fatigue in sarcoidosis and exercise tolerance, dyspnea, and quality of life

N17 Frequency of infliximab-induced skin lesions and their impact on quality of life in inflammatory bowel disease patients treated with infliximab

Pre-Courtship Behavior and the Effect of Age on Its Duration in Diatraea magnifactella (Lepidoptera: Crambidae)

P603 Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease

P177 Lower vedolizumab trough levels before interval shortening are not predictive of success of the intervention

P344 Effectiveness and safety of switching patients with inflammatory bowel disease from originator infliximab to CT-P13: systematic review and meta-analysis

P720 Drug survival of first-line biologics in inflammatory bowel disease: large single-centre experience from UR-CARE

Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn’s and Colitis Organisation [ECCO] Position Paper

Sorry Works! Disclosure, Apology, and Relationships Prevent Medical Malpractice Claims

Baseline Data and Measurement Instruments Reported In Observational Studies In Inflammatory Bowel Disease: Results From A Systematic Review

P041 Characterization of cytokine and drug concentrations in serum, mucosa and faeces during induction treatment of moderate-to-severe ulcerative colitis with anti-TNF monoclonal antibodies

A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence

Sorry Works! Disclosure, Apology, and Relationships Prevent Medical Malpractice Claims

P311 Reliability of computed tomography enterography for evaluation of stricturing Crohn’s disease: Development of a Crohn’s disease stricture index

P495 Vedolizumab trough concentrations and histological remission in Ulcerative Colitis: Results from the LOVE-UC study

P686 Neither high infliximab maintenance doses nor high trough levels trigger skin side effects of the drug: a prospective cross-sectional study

DOP63 Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease

Physician, Protect Thyself: 7 Simple Ways NOT to Get Sued for Medical Malpractice

Genetically determined thrombophilia as a cause of acute abdomen

Suchergebnisse filtern